Related Experiment Videos
Streptozotocin: an inactive agent in small cell carcinoma
Cancer Clinical Trials
|January 1, 1979
Summary
Streptozotocin showed no effectiveness in treating advanced small cell lung cancer. This study found no objective responses in 15 patients, confirming its inactivity as a standalone therapy for this condition.
Area of Science:
- Oncology
- Medical Research
Background:
- Small cell lung carcinoma (SCLC) is an aggressive form of lung cancer.
- Effective single-agent therapies for advanced SCLC are crucial.
Purpose of the Study:
- To evaluate the efficacy of streptozotocin as a single agent in patients with advanced small cell lung carcinoma.
Main Methods:
- Fifteen patients with advanced SCLC received treatment with streptozotocin.
- A literature review was conducted to assess previous studies on streptozotocin in SCLC.
Main Results:
- No objective responses were observed in the 15 treated patients.
- A cumulative review of 56 patients indicated a lack of objective response to streptozotocin.
Conclusions:
- Streptozotocin is inactive as a single agent for treating advanced small cell lung carcinoma.
- Further investigation into combination therapies or alternative agents is warranted.